These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 20012242)
1. Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Romão PR; Lemos JC; Moreira J; de Chaves G; Moretti M; Castro AA; Andrade VM; Boeck CR; Quevedo J; Gavioli EC Neurotox Res; 2011 Jan; 19(1):73-80. PubMed ID: 20012242 [TBL] [Abstract][Full Text] [Related]
2. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
3. Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Streck EL; Scaini G; Rezin GT; Moreira J; Fochesato CM; Romão PR Metab Brain Dis; 2008 Dec; 23(4):485-92. PubMed ID: 18815873 [TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355 [TBL] [Abstract][Full Text] [Related]
6. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045 [TBL] [Abstract][Full Text] [Related]
7. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD; AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563 [TBL] [Abstract][Full Text] [Related]
8. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066 [TBL] [Abstract][Full Text] [Related]
9. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. Pillay P; Ford N; Shubber Z; Ferrand RA PLoS One; 2013; 8(7):e68995. PubMed ID: 23894391 [TBL] [Abstract][Full Text] [Related]
10. Long-term efavirenz exposure induced neuroinflammation and cognitive deficits in C57BL/6 mice. Zhang R; Bao J; Qiao J; Li W; Qian F; Hu K; Sun B Biochem Biophys Res Commun; 2021 Dec; 584():46-52. PubMed ID: 34768081 [TBL] [Abstract][Full Text] [Related]
11. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya. Ngayo MO; Oluka M; Bulimo WD; Okalebo FA Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325 [TBL] [Abstract][Full Text] [Related]
12. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672 [TBL] [Abstract][Full Text] [Related]
14. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001 [TBL] [Abstract][Full Text] [Related]
15. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort. Bock P; Fatti G; Grimwood A Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113 [TBL] [Abstract][Full Text] [Related]
16. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877 [TBL] [Abstract][Full Text] [Related]
17. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Tohyama J; Billheimer JT; Fuki IV; Rothblat GH; Rader DJ; Millar JS Atherosclerosis; 2009 Jun; 204(2):418-23. PubMed ID: 18990393 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776 [TBL] [Abstract][Full Text] [Related]
19. Effect of antiretroviral drugs on the DNA damage in mice. de Oliveira HM; Damiani AP; Dias Rde O; Romão PR; Andrade VM Environ Toxicol Pharmacol; 2014 Jan; 37(1):390-5. PubMed ID: 24441026 [TBL] [Abstract][Full Text] [Related]
20. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort. Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]